Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Assembly Biosciences (ASMB) over the last 9 years, with Q3 2025 value amounting to $42.4 million.

  • Assembly Biosciences' Current Deferred Revenue fell 3495.72% to $42.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year decrease of 3495.72%. This contributed to the annual value of $37.6 million for FY2024, which is 5640.25% down from last year.
  • Assembly Biosciences' Current Deferred Revenue amounted to $42.4 million in Q3 2025, which was down 3495.72% from $40.9 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Current Deferred Revenue registered a high of $86.3 million during Q4 2023, and its lowest value of $2.7 million during Q3 2021.
  • In the last 5 years, Assembly Biosciences' Current Deferred Revenue had a median value of $40.8 million in 2025 and averaged $37.8 million.
  • As far as peak fluctuations go, Assembly Biosciences' Current Deferred Revenue plummeted by 7506.45% in 2021, and later skyrocketed by 305748.26% in 2023.
  • Over the past 5 years, Assembly Biosciences' Current Deferred Revenue (Quarter) stood at $2.7 million in 2021, then changed by 0.0% to $2.7 million in 2022, then surged by 3057.48% to $86.3 million in 2023, then tumbled by 56.4% to $37.6 million in 2024, then increased by 12.6% to $42.4 million in 2025.
  • Its last three reported values are $42.4 million in Q3 2025, $40.9 million for Q2 2025, and $40.8 million during Q1 2025.